Last updated on April 2018

Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9)

Brief description of study

Bladder cancer (BC), the second most common urological malignancy, is an important public health issue. One of the main challenges in the treatment of bladder cancer if the prevention of recurrences of non-invasive tumors, which is also associated with significant costs.

The current study will investigate optimal treatment of patients with bladder cancer with high risk of tumor recurrence but low risk of progression. The main interest is comparison of photodynamic (PDD) bladder tumor resection (TUR-BR)to traditional TUR-BT. Also the efficacy of adjuvant optimized mitomycin-C is compared to patients with no adjuvant treatment.

Clinical Study Identifier: NCT01675219

Contact Investigators or Research Sites near you

Start Over

Riikka Järvinen, MD

HYKS Peijas Hospital
Helsinki, Finland
  Connect »

Eero Kaasinen, Md, PhD

Hyvink District Hospital
Hyvinkää, Finland
  Connect »

Aaltomaa Sirpa, MD

Kuopio University Hospital
Kuopio, Finland
  Connect »

Tapanki Liukkonen, MD

Mikkeli Central Hospital
Mikkeli, Finland
  Connect »

Markku Vaarala, MD

Oulu University Hospital
Oulu, Finland
  Connect »

Marjo Seppänen, MD

Satakunnan keskussairaala
Pori, Finland
  Connect »

Timo Marttila, MD

Sein joki Central Hospital
Seinäjoki, Finland
  Connect »

Tarmo Pekkarinen, MD

Hatanp n sairaala
Tampere, Finland
  Connect »

Juha Koskimäki, MD

Tampere University Hospital
Tampere, Finland
  Connect »

Peter J. Boström, MD, PhD

Turku University Hospital
Turku, Finland
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.